Glycotope Biotechnology GmbH - History
2008 | Glycotope Biotechnology GmbH, a fully consolidated subsidiary of Berlin-based Glycotope GmbH, has acquired the biopharmaceutical production facility and diagnostic business of ORPEGEN Pharma GmbH |
|---|---|
2004 | Inauguration of the new multi-purpose biotechnology facility |
2004 | Development of MHC class I peptide tetramers for determination of the cellular immune response. |
2003 | The reagent kits MIGRATEST, PHAGOTEST, PHAGOBURST (BURSTTEST), NKTEST and BASOTEST are registered in full compliance to the European guideline 98/79/EC for In-Vitro Diagnostics (IVD). |
2002 | 20 years jubilee. Investment by High Tech Private Equity. |
2001 | GMP production of glycoproteins for therapy. |
1999 | GMP production of monoclonal antibodies for in-vivo diagnostics. |
1997 | BASOTEST, first quantitative diagnostic for allergies on market. |
1994 | EPO Project terminated due to patent debates between USA and Europe. |
1989 | Contract development and production of recombinant human Erythropoietin (rhEPO) for clinical trials up to phase III, successfully completed in 1993 . |
1987 | Participation of Heidelberg Cement AG as investing partner. |
1985 | 1985 Participation of Deutsche Shell AG as investing partner. |
1984 | Commencement of the manufacture of amino acid derivatives and pharmaceutical peptides |
1982 | Foundation of ORPEGEN, predecessor of ORPEGEN Pharma. |